UK markets closed
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • FTSE 250

    22,775.28
    +283.88 (+1.26%)
     
  • AIM

    1,262.60
    +9.91 (+0.79%)
     
  • GBP/EUR

    1.1495
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.70%)
     
  • BTC-GBP

    41,351.29
    -1,072.96 (-2.53%)
     
  • CMC Crypto 200

    1,480.07
    +44.29 (+3.08%)
     
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • DOW

    34,777.76
    +229.26 (+0.66%)
     
  • CRUDE OIL

    64.82
    -0.08 (-0.12%)
     
  • GOLD FUTURES

    1,832.00
    +0.70 (+0.04%)
     
  • NIKKEI 225

    29,357.82
    +26.42 (+0.09%)
     
  • HANG SENG

    28,610.65
    -26.85 (-0.09%)
     
  • DAX

    15,399.65
    +202.95 (+1.34%)
     
  • CAC 40

    6,385.51
    +28.42 (+0.45%)
     

Analysts optimistic on Astrazeneca outlook

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Michael Green
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The Astrazeneca (LON:AZN) share price has risen by 2.76% over the past month and it’s currently trading at 8543. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue.

According to the company’s analysts, there are certainly reasons to think it will continue to perform well in the year ahead. In terms of trading recommendations, Astrazeneca currently has:

  • 8 Buy recommendations

  • 2 Hold recommendations

  • 1 Sell recommendations

This suggests that analysts are generally positive about the outlook.

GET MORE DATA-DRIVEN INSIGHTS INTO LON:AZN »

Researching beyond broker forecasts

At its current price of 8543, shares in Astrazeneca are trading at a discount of -7.23% to its 52 week high price. The 1-year performance of the shares has been 32.7%.

While analyst forecasts can be a useful guide to what City 'experts' think about a stock's near term future, they can be unreliable. To get a better idea about the strengths and weaknesses of Astrazeneca it's worth doing some investigation yourself.

There are all sorts of factors that could affect Astrazeneca's share price this year – we simplify them into easy to understand scores with our Stockopedia StockReport. Click here to take a look at the StockReport for Astrazeneca – you might discover some surprising things you didn’t know.